洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

60 Degrees Pharmaceuticals Inc

  • 存续
  • 上市
公司全称:60 Degrees Pharmaceuticals Inc
国家/地区:美国/——
类型:抗疟疾药物研发商
收藏
公司介绍:
60 Degrees Pharmaceuticals, Inc.是特拉华州的一家公司,成立于2022年6月1日。该公司是一家以成长为导向的专业制药公司,其目标是利用前沿的生物科学和应用研究进一步开发和商业化预防和治疗传染病的新疗法。该公司已成功获得监管部门对Arakoda的批准,这是一种自2019年底上市的疟疾预防疗法。目前,60P正在开发的产品线涵盖了通过阿拉科达和塞尔戈西维尔开发新冠肺炎、真菌、蜱传和其他病毒性疾病的项目。

基本信息

成立时间:

2010-01-01

员工人数:

15人以下

联系电话:

1-202-3275422

地址:

1025 Connecticut Avenue NW Suite 1000 Washington D.C. 20036

公司官网:

60degreespharma.com

企业画像

团队信息

Geoffrey Dow ——
Chief Executive Officer,President and Director,Chairman 薪酬:
个人简介:——
Geoffrey Dow ——
Chief Executive Officer,President and Director,Chairman 薪酬:
个人简介:Geoffrey Dow,is 60 Degrees Pharmaceuticals, Inc. Chief Executive Officer, President, and is also 60 Degrees Pharmaceuticals, Inc. sole Director. Dr. Dow has over 20 years of product development experience in tropical diseases and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory roles in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60P in 2010. Since then, he has been involved in various projects, including leading the project development team in securing FDA-regulatory approval for Tafenoquine (as Arakoda) for malaria prophylaxis, securing a supply chain and access relating to Arakoda, managing post-marketing regulatory commitments, ensuring the successful prosecution of supporting patents on which Dr. Dow was an inventor, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. Dr. Dow has also published a number of important safety reviews, clinical trials, non-clinical studies, on which he was a thought leader or contributor, which dispelled many of the myths about 8-aminoquinolines. As a scientist, experienced industry project manager and inventor, Dr. Dow's ultimate goal is to develop and secure the regulatory approval and commercial success of products, old and new, for new indications in infectious disease. Dr. Dow received a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia ("Murdoch") in 1994, a Ph.D. in Veterinary and Biomedical Science from Murdoch in 2000 and an MBA from the University of Maryland at College Park in 2012.
Tyrone Miller ——
Chief Financial Officer 薪酬:
个人简介:Tyrone Miller,is 60 Degrees Pharmaceuticals, Inc. Chief Financial Officer. Mr. Miller joined 60 Degrees Pharmaceuticals, Inc. in 2014 and has held a number of roles since then, including Treasurer. He worked with the founder and Chief Executive Officer of 60P and raised over $6 million in external financing. Mr. Miller also established a multinational financial reporting system and worked with consultants in designing tax and credit strategies. He also provides key strategic advice in areas of financing and business planning to 60P. In addition, he is the founder and Principal of Tax & Accounting Practice at Miller Tax & Advisory since 2011. In that role, Mr. Miller advises owners of closely held businesses on accounting, financial and tax matters and has designed accounting systems for private sector businesses. From 2002 to 2011, he was a Senior Accountant at Sachs Figurelli, LLC, where he prepared and processed corporate and individual tax returns, consulted on reengineering accounting processes for construction, restaurant and professional services businesses and managed staff in preparation and processing of payroll and personal property returns. Mr. Miller is currently a Certified Public Accountant. He received a Bachelor's of Business Administration with a concentration in International Business from Emory University in 1996.
Bryan Smith ——
Chief Medical Officer 薪酬:——
个人简介:Bryan Smith,is 60 Degrees Pharmaceuticals, Inc. Chief Medical Officer. Dr. Smith is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development and translational medicine and is a retired military colonel with over 30 years of governmental research and leadership experience. He joined 60 Degrees Pharmaceuticals, Inc. in 2016 as Chief Medical Officer and works with other members of the senior management team to establish all functional areas, including complying with national and international laws and regulations and developing and overseeing research and development projects and agenda. He also is currently a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC since 2019, where he is responsible for developing clinical development plans for therapeutic products, managing clinical and regulatory projects and designing and writing clinical trial protocols. Since 2016, Dr. Smith has been the Chief Medical Officer and member of Amivas LLC, where he establishes all functional areas required to successfully secure FDA approvals. In addition, from 2016 to 2019, he was the Principal Medical Consultant at Clinical Network Services, Inc., where he provided required medical, clinical pharmacology, regulatory, translational medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small molecules and large molecules in a range of therapeutic areas. Dr. Smith received a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.
Geoffrey Dow ——
Chief Executive Officer,President and Director,Chairman 薪酬:
个人简介:——

企业动态

60度制药公司宣布,其正在进行的一项随机、双盲、安慰剂对照的临床试验已成功招募了2026年蜱虫季节的第一位患者。该试验旨在评估Tafenoquine在治疗住院巴贝斯虫病人类患者中的疗效和安全性。试验预计将在美国东北部的五个临床地点进行,目标是招募至少24名患者。根据目前的进度,试验可能最早在2026年7月初完成最低招募人数。Tafenoquine目前在美国作为ARAΚΟΔΑ®被批准用于疟疾预防,但尚未被证明对治疗或预防巴贝斯虫病有效,也未获得美国食品药品监督管理局(FDA)的此类批准。
2026年1月22日,专注于开发新药物的60度制药公司宣布与Runway Health合作,通过Runway Health的旅行医疗平台,为计划前往疟疾流行地区的国际旅行者提供ARAKODA(他非诺quine)预防疟疾的便利。ARAKODA是美国唯一批准的广谱、每周一次的疟疾预防药物。Runway Health是一个面向患者的直接医疗平台,允许成年人在前往可能存在疟疾等疾病的地区旅行前进行在线医生咨询。如果医生开具处方,药物将无缝地在家递送。该合作从2026年4月2日开始,为60度制药的ARAKODA营销策略增添了新的平台,符合条件的用户可以匹配他们的旅行行程与由美国持牌医疗保健提供者设计的个性化医疗治疗方案。ARAKODA(他非诺quine)是一种抗疟疾药物,用于预防18岁及以上患者的疟疾。它在美国以ARAKODA®的名称获得批准,用于疟疾预防。
60度制药公司近日宣布,一项由北卡罗来纳州立大学研究人员开展的研究发现,在50名慢性疲劳症患者中,有24%的患者感染了由蜱虫传播的巴贝虫病。这一研究结果支持了美国传播性疾病社区长期持有的理论,即巴贝虫感染可能与慢性疾病有关,特别是巴贝虫感染可能会延长慢性疲劳症患者的康复时间。此外,该研究结果也强调了B-Free慢性巴贝虫病研究的重要性,该研究正在评估塔芬喹(ARAKODA)方案在90天内治疗慢性巴贝虫病引起的严重疲劳的疗效和安全性。塔芬喹在美国已获批准用于疟疾预防。
60度制药公司(60 Degrees Pharmaceuticals, Inc.)宣布,在6个月的商业试点项目取得积极成果后,计划扩大其销售和市场计划。试点结果显示,对ARAΚΟΔΑ®产品的需求增加。公司计划增加内部销售代表人数,与GoodRx合作扩大销售覆盖范围,并加强数字营销活动。此外,公司还将根据美国食品药品监督管理局(FDA)的反馈,增加至少两个贝氏疟疾治疗临床试验的诊所。这些举措旨在扩大市场覆盖范围,加速ARAΚΟΔΑ的销售,并支持医疗保健提供者和患者。
60度制药公司宣布,其B-FREE慢性巴贝斯虫病研究已开始招募患者。该研究是一项为期约12个月的2期开放标签研究,旨在评估Tafenoquine治疗方案在90天内对慢性巴贝斯虫病患者严重疲劳和寄生虫根除的疗效和安全性。目前美国每年约有4,400例可诊断的慢性巴贝斯虫病病例,但尚无美国食品药品监督管理局(FDA)批准的治疗方法。该研究旨在确定巴贝斯虫感染是否可以通过验证的分子测试在慢性巴贝斯虫病患者中得到确认,从而帮助确定患者群体的真实规模。

融资信息

更多
公布时间
企业名称
类型
行业领域
融资轮次
融资金额
投资方
详情

2025-01-30

60 Degrees Pharmaceuticals Inc

抗疟疾药物研发商

医药研发/制造
化学&生物药

增发
——

2024-09-06

60 Degrees Pharmaceuticals Inc

抗疟疾药物研发商

医药研发/制造
化学&生物药

IPO后其他轮次
——
——

2024-01-31

60 Degrees Pharmaceuticals Inc

抗疟疾药物研发商

医药研发/制造
化学&生物药

增发
——

2023-07-12

60 Degrees Pharmaceuticals Inc

抗疟疾药物研发商

医药研发/制造
化学&生物药

上市
——

财务数据

更多
损益表
资产负债表
现金流量表
按年度
按季度
截止日期
2024-12-31
2023-12-31
2022-12-31
2021-12-31
截止日期
2025-09-30
2025-06-30
2025-03-31
2024-12-31
开通会员查看该企业财务数据
免费领取会员
相关财报
年份
一季报
中报
三季报
年报

2026年

——
——
——

2025年

——

2024年

2023年

——

企业公告

公告标题
公告类型
公告日期

监管和公司治理

2026-07-09

监管和公司治理

2026-06-03

产品管线

管线概览
药物发现
临床前
申报临床
I期临床
II期临床
III期临床
申请上市
批准上市
其他/失败
/未知
申请试用摩熵医药企业版,可查看完整内容
免费申请试用
药物研发
药品名称
研发企业
靶点
治疗领域
适应症
研发进展
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

注册申报

受理号
药品名称
CDE企业名称
申请类型
注册类型
承办日期
状态开始日期
办理状态
审评
结论
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

临床进展

试验题目
药物名称
靶点
适应症
试验分期
试验状态
申办单位
登记号
首次公示
信息日期
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

上市信息

批准文号
药品名称
规格
剂型
生产单位
上市许可
持有人
药品类型
国产或
进口
批准日期
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

招投标信息

药品名称
剂型
规格
转化
系数
最小制剂单位价格(元)
价格(元)
生产企业
投标企业
省份
公布时间
网页链接
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

过评一致性

企业
品种
规格
剂型
过评情况
过评时间
注册分类
上市药物目录集(收录时间)
申请试用摩熵医药企业版,可查看完整内容
免费申请试用

知识产权

专利标题
申请号/月
公开号/日
相关药物
产品类型
技术分类
当前法律
状态
查看该企业更多专利数据,请前往“摩熵专利”平台
申请试用
投融资
目录
基本信息
工商信息
团队信息
企业动态
融资信息
交易事件
财务数据
企业公告
企业研报
产品管线
注册申报
临床进展
上市信息
招投标信息
过评一致性
知识产权
相关投融资企业
最新投融资资讯
企业竞争格局数据库
添加收藏
    新建收藏夹
    取消
    确认